- Projects & figures
- News & Events
- Managing your project
- About ERC
About the size of a big cherry, the first-of-its-kind 3D printed heart has cells, blood vessels, ventricles and chambers. This feat is the work of Prof. Tal Dvir and his team at Tel Aviv University. They managed to engineer such miniature organs using cells and biological materials that are originated from human patients. Besides the remarkable technical achievement, this breakthrough could potentially be the answer to the shortage of organ donors in the future.
At the forefront of medicine, gene therapy is based on the insertion of genes into an individual's cells and tissues to treat a disease. Scientists are currently testing several approaches to this experimental technique. One of them, Prof. Seppo Ylä-Herttuala, intends to develop a novel method to treat myocardial ischemia by activating endogenous genes to propel angiogenesis. If successful, he will open a new era in gene therapy.
More than 100 million people worldwide suffer from valvular heart disease, affecting one or more of the heart’s four valves and causing breathlessness, chest pain, dizziness and fainting. If severe valvular heart disease is not properly treated, chances of surviving decrease, especially in the elderly. The only effective therapy is heart valve replacement, which may entail some risks and lead to revision surgeries. What can be done to improve safety and durability of artificial heart valves?
More than 3.5 million new people are diagnosed with heart failure every year in Europe, with a long-term prognosis of 50% mortality within four years. There is urgent need for more innovative, regenerative therapies with the potential to change the course of the condition.